Skip to main content

Abpro Holdings, Inc.

corporate_fare Company Profile

Abpro Holdings, Inc.

ABPO·OTC·Life Sciences·CIK 0001893219

Abpro Holdings, Inc. is a biotechnology company that develops advanced antibody treatments for patients with severe and life-threatening diseases. The company focuses on creating new antibodies using its specialized discovery and engineering platforms. Its primary areas of focus are immuno-oncology, ophthalmology, and infectious disease. On November 13, 2024, Atlantic Coastal Acquisition Corp. II (ACAB) completed a merger with Abpro Corporation (Legacy Abpro). Following the merger, ACAB changed its name to Abpro Holdings, Inc., and Legacy Abpro became a wholly owned subsidiary of the company. Shares of Abpro Holdings, Inc. common stock began trading on the Nasdaq Global Market on November 14, 2024. However, due to multiple Nasdaq continued listing non-compliance issues, the company received a delisting notice effective February 23, 2026. Its securities currently trade on the OTC Pink Limited Market under the ticker symbol ABPO for common shares. The company appealed the Nasdaq delisting determination on March 18, 2026. For financial reporting purposes, the merger was treated as a reverse recapitalization, with ACAB considered the acquired company and Legacy Abpro the acquirer. The company's operations prior to the merger are those of Legacy Abpro.

Abpro Holdings, Inc. (OTC:ABPO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 2 items for ABPO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-06-04, rated 7/10. Across its 2 most recent items scored 7 or higher, the top rating is 9/10, with 1 rated 8 or above. Recent SEC coverage for ABPO spans 10-K.

Recent high-impact activity:

  • Nasdaq Reaffirms Delisting Decision for Abpro Holdings, Stock to Move to OTC Pink
  • Abpro Holdings Faces Going Concern Doubt, Nasdaq Delisting, and Internal Control Weaknesses Amid Cash Crunch

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 15,840 shares in ABPO as of the October 30, 2026 settlement, a 1.6% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 76.1% of ABPO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)15,840 shares as of October 30, 2026
Change vs prior period▼ 1.6%
Days to cover1.00 at avg daily volume of 34,808
Daily short volume (FINRA facilities)76.1% of 256,303 shares on November 20, 2026
5-day average short volume64.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$0.90 +28.77% today
52-week range · as of 2026-04-15 $0.0866 – $409.5
Market cap
$5.31M
Volume
256.3K (11.4× avg)
3-mo avg 22.5K
Live data · 2026-11-21 08:50 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ABPO - Latest Insights

ABPO
Jun 04, 2026, 5:13 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.20622
Real-time Price: $0.900 info
Change: +$0.69378 (+336%) info
Market Cap: $5.306M info
ABPO
Apr 15, 2026, 5:27 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.1151
Real-time Price: $0.900 info
Change: +$0.7849 (+682%) info
Market Cap: $5.306M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets